Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP in Patients After Coronary Intervention Therapy

NCT07933757 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP in Patients After Coronary Intervention Therapy
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 10, 2026
Completion date
November 10, 2027
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary heart disease, inflammation

Arms

As registered; 5 arms.

  • Control group No intervention

    Standard treatment for coronary heart disease

  • Colchicine group ExperimentalColchicine

    Colchicine+standard treatment for coronary heart disease

  • Eplerenone group ExperimentalEplerenone

    Eplerenone+standard treatment for coronary heart disease

  • Leflunomide group ExperimentalLeflunomide

    Leflunomide+standard treatment for coronary heart disease

  • Artesunate group ExperimentalArtesunate

    Artesunate+standard treatment for coronary heart disease

Primary endpoints

Registered primary outcome measures; 1 primary.

  • The change in hsCRP 4 weeks

    The change in hsCRP compared to baseline

Papers

PubMed papers this trial cites; 2 papers, results papers first, then newest first.

Source: PubMed, NCBI/NLM (public domain).

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Artesunate 2 Orange Book patentsPatent cliff February 16, 2044 (Orange Book patent)
    • US 12121506; expires February 16, 2044; assignee Amivas Inc.
    • US 12390442; expires February 16, 2044; assignee Amivas Inc.
  • Colchicine 41 Orange Book patentsPatent cliff December 20, 2037 (Orange Book patent)
    • US 10226423; expires December 20, 2037; assignee RxOmeg Therapeutics LLC
    • US 10383820; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
    • US 10383821; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
    • US 12274751; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
    • US 12514819; expires November 22, 2036; assignee not stated
    • +36 more patents
  • Eplerenone 1 Orange Book patent
    • US 4559332; expires August 11, 2007; assignee Ciba-Geigy

Lead sponsor's other trials

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, most recent start first.

Similar trials

Same condition (Coronary Disease) and phase, most recent start first.